
    
      This is a cross-sectional, observational patient survey study. Study subjects will be adult
      commercial members of the large US health plan affiliated with Optum with evidence of T2D
      initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey
      mailing.
    
  